DexCom, Inc. (DXCM)
87.90
-1.81
(-2.02%)
USD |
NASDAQ |
Sep 04, 16:00
88.09
+0.19
(+0.22%)
After-Hours: 20:00
DexCom Research and Development Expense (Quarterly) : 153.00M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 153.00M |
| March 31, 2026 | 145.30M |
| December 31, 2025 | 148.20M |
| September 30, 2025 | 157.50M |
| June 30, 2025 | 148.20M |
| March 31, 2025 | 145.20M |
| December 31, 2024 | 139.50M |
| September 30, 2024 | 135.40M |
| June 30, 2024 | 136.00M |
| March 31, 2024 | 141.50M |
| December 31, 2023 | 133.20M |
| September 30, 2023 | 131.40M |
| June 30, 2023 | 119.30M |
| March 31, 2023 | 119.00M |
| December 31, 2022 | 116.30M |
| September 30, 2022 | 110.30M |
| June 30, 2022 | 121.70M |
| March 31, 2022 | 135.90M |
| December 31, 2021 | 236.90M |
| September 30, 2021 | 128.80M |
| June 30, 2021 | 129.10M |
| March 31, 2021 | 109.40M |
| December 31, 2020 | 119.20M |
| September 30, 2020 | 87.70M |
| June 30, 2020 | 79.90M |
| Date | Value |
|---|---|
| March 31, 2020 | 73.10M |
| December 31, 2019 | 78.80M |
| September 30, 2019 | 66.70M |
| June 30, 2019 | 69.00M |
| March 31, 2019 | 59.00M |
| December 31, 2018 | 275.30M |
| September 30, 2018 | 50.10M |
| June 30, 2018 | 47.20M |
| March 31, 2018 | 44.80M |
| December 31, 2017 | 48.70M |
| September 30, 2017 | 43.30M |
| June 30, 2017 | 45.30M |
| March 31, 2017 | 48.10M |
| December 31, 2016 | 43.70M |
| September 30, 2016 | 43.90M |
| June 30, 2016 | 36.30M |
| March 31, 2016 | 32.20M |
| December 31, 2015 | 28.50M |
| September 30, 2015 | 64.80M |
| June 30, 2015 | 24.40M |
| March 31, 2015 | 19.80M |
| December 31, 2014 | 21.60M |
| September 30, 2014 | 19.40M |
| June 30, 2014 | 15.80M |
| March 31, 2014 | 13.30M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Abbott Laboratories | 892.00M |
| Insulet Corp. | 88.10M |
| Baxter International, Inc. | 125.00M |
| Globus Medical, Inc. | 36.32M |
| Stryker Corp. | 424.00M |